Achieving Affordable Individualized Vaccines for Cancer Patients Faster

As BioNTech, Moderna, and Merck have recently released positive phase II clinical results for personalized cancer vaccines, the whole industry is now racing to develop affordable and efficacious individualized cancer therapies to induce an immune response.

Here's why you can't miss this:

• Pre-Conference Manufacturing Focus Day: Exploring critical challenges with innovative sequencing techniques, emphasizing the crucial role of bioinformatics in the production process, and rethinking the scale of drug development to deliver highly effective therapies at a more accessible cost.
• Coverage of Individualized approaches across several modalities: From RNA and DNA, to peptides, viral, and dendritic cell, you can uncover how industry leading companies are conquering common challenges, developing novel bioinformatic strategies, and achieving clinical efficacy.
• 15+ Deep dive case studies from 18+ C-Level speakers: Dive into the latest case studies spanning from sequencing tumors and identifying neoantigen targets to administering vaccines to patients in the clinic.

This is your unique opportunity to join CureVac, Imvax, BioNTech, and more at the Personalized Cancer Vaccine Summit this December 3-5 in Boston! With interactive networking opportunities along with our C-Level speaker faculty, you'll gain valuable insights into individualized cancer vaccine approaches, and learn how common challenges are being addressed head-on.

Download the Full Event Guide Here.

Registration is now open, with group discounts up to 20% and additional savings on offer. Secure your spot today.